Cargando…
VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
BACKGROUND: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210095/ https://www.ncbi.nlm.nih.gov/pubmed/22029879 http://dx.doi.org/10.1186/1465-9921-12-141 |
_version_ | 1782215704086315008 |
---|---|
author | Hamidi, Sayyed A Lin, Richard Z Szema, Anthony M Lyubsky, Sergey Jiang, Ya Ping Said, Sami I |
author_facet | Hamidi, Sayyed A Lin, Richard Z Szema, Anthony M Lyubsky, Sergey Jiang, Ya Ping Said, Sami I |
author_sort | Hamidi, Sayyed A |
collection | PubMed |
description | BACKGROUND: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was fully corrected by VIP. The objectives of this investigation were to answer the questions: 1) Can VIP protect against PH in other experimental models? and 2) Does combining VIP with an endothelin (ET) receptor antagonist bosentan enhance its efficacy? METHODS: Within 3 weeks of a single injection of monocrotaline (MCT, s.c.) in Sprague Dawley rats, PAH developed, manifested by pulmonary vascular remodeling, lung inflammation, RV hypertrophy, and death within the next 2 weeks. MCT-injected animals were either untreated, treated with bosentan (p.o.) alone, with VIP (i.p.) alone, or with both together. We selected this particular combination upon finding that VIP down-regulates endothelin receptor expression which is further suppressed by bosentan. Therapeutic outcomes were compared as to hemodynamics, pulmonary vascular pathology, and survival. RESULTS: Treatment with VIP, every other day for 3 weeks, begun on the same day as MCT, almost totally prevented PAH pathology, and eliminated mortality for 45 days. Begun 3 weeks after MCT, however, VIP only partially reversed PAH pathology, though more effectively than bosentan. Combined therapy with both drugs fully reversed the pathology, while preventing mortality for at least 45 days. CONCLUSIONS: 1) VIP completely prevented and significantly reversed MCT-induced PAH; 2) VIP was more effective than bosentan, probably because it targets a wider range of pro-remodeling pathways; and 3) combination therapy with VIP plus bosentan was more effective than either drug alone, probably because both drugs synergistically suppressed ET-ET receptor pathway. |
format | Online Article Text |
id | pubmed-3210095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32100952011-11-08 VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension Hamidi, Sayyed A Lin, Richard Z Szema, Anthony M Lyubsky, Sergey Jiang, Ya Ping Said, Sami I Respir Res Research BACKGROUND: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was fully corrected by VIP. The objectives of this investigation were to answer the questions: 1) Can VIP protect against PH in other experimental models? and 2) Does combining VIP with an endothelin (ET) receptor antagonist bosentan enhance its efficacy? METHODS: Within 3 weeks of a single injection of monocrotaline (MCT, s.c.) in Sprague Dawley rats, PAH developed, manifested by pulmonary vascular remodeling, lung inflammation, RV hypertrophy, and death within the next 2 weeks. MCT-injected animals were either untreated, treated with bosentan (p.o.) alone, with VIP (i.p.) alone, or with both together. We selected this particular combination upon finding that VIP down-regulates endothelin receptor expression which is further suppressed by bosentan. Therapeutic outcomes were compared as to hemodynamics, pulmonary vascular pathology, and survival. RESULTS: Treatment with VIP, every other day for 3 weeks, begun on the same day as MCT, almost totally prevented PAH pathology, and eliminated mortality for 45 days. Begun 3 weeks after MCT, however, VIP only partially reversed PAH pathology, though more effectively than bosentan. Combined therapy with both drugs fully reversed the pathology, while preventing mortality for at least 45 days. CONCLUSIONS: 1) VIP completely prevented and significantly reversed MCT-induced PAH; 2) VIP was more effective than bosentan, probably because it targets a wider range of pro-remodeling pathways; and 3) combination therapy with VIP plus bosentan was more effective than either drug alone, probably because both drugs synergistically suppressed ET-ET receptor pathway. BioMed Central 2011 2011-10-26 /pmc/articles/PMC3210095/ /pubmed/22029879 http://dx.doi.org/10.1186/1465-9921-12-141 Text en Copyright ©2011 Hamidi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Hamidi, Sayyed A Lin, Richard Z Szema, Anthony M Lyubsky, Sergey Jiang, Ya Ping Said, Sami I VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension |
title | VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension |
title_full | VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension |
title_fullStr | VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension |
title_full_unstemmed | VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension |
title_short | VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension |
title_sort | vip and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210095/ https://www.ncbi.nlm.nih.gov/pubmed/22029879 http://dx.doi.org/10.1186/1465-9921-12-141 |
work_keys_str_mv | AT hamidisayyeda vipandendothelinreceptorantagonistaneffectivecombinationagainstexperimentalpulmonaryarterialhypertension AT linrichardz vipandendothelinreceptorantagonistaneffectivecombinationagainstexperimentalpulmonaryarterialhypertension AT szemaanthonym vipandendothelinreceptorantagonistaneffectivecombinationagainstexperimentalpulmonaryarterialhypertension AT lyubskysergey vipandendothelinreceptorantagonistaneffectivecombinationagainstexperimentalpulmonaryarterialhypertension AT jiangyaping vipandendothelinreceptorantagonistaneffectivecombinationagainstexperimentalpulmonaryarterialhypertension AT saidsamii vipandendothelinreceptorantagonistaneffectivecombinationagainstexperimentalpulmonaryarterialhypertension |